REPH Recro Pharma Inc.

8.36
-0.04  -0%
Previous Close 8.4
Open 8.47
Price To Book 13.27
Market Cap 179551883
Shares 21,477,498
Volume 131,208
Short Ratio
Av. Daily Volume 126,370

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL announced May 24, 2018. New PDUFA date March 24, 2019.
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery

Latest News

  1. Edited Transcript of REPH earnings conference call or presentation 19-Feb-19 1:00pm GMT
  2. Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine
  3. Recro Pharma: 4Q Earnings Snapshot
  4. Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
  5. Recro Pharma, Inc. to Host Earnings Call
  6. What's in the Cards for Bausch Health (BHC) Q4 Earnings?
  7. 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
  8. Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019
  9. Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville
  10. Could Recro Pharma, Inc.’s (NASDAQ:REPH) Investor Composition Influence The Stock Price?
  11. 5 Domestic Stocks to Gain From Thaw in Trade Talks
  12. Recro Pharma Amends Athyrium Credit Facility
  13. Recro Pharma restructures licensing agreement for non-opioid pain medicine
  14. Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
  15. Recro Pharma Announces Presentation of New Data Demonstrating IV Meloxicam’s Effect on Platelet Function at the 72nd PostGraduate Assembly in Anesthesiology
  16. Our Take On Recro Pharma Inc’s (NASDAQ:REPH) CEO Salary
  17. Edited Transcript of REPH earnings conference call or presentation 7-Nov-18 1:00pm GMT
  18. Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia
  19. Recro Pharma to Participate in Upcoming Investor Conferences